Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion ...

Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

Dyne and FDA agreed that the next step toward ... index (CASI-22), muscle strength as assessed by Quantitative Muscle Testing (QMT), performance on both the 10-Meter Walk/Run Test (10MWR) and ...

Shares of Dyne Therapeutics (NASDAQ:DYN) plunged 23% after the biotech firm announced changes to its regulatory strategy for ...

DYNE-101 demonstrated an improvement in muscle strength and early and sustained potential benefit in the 10-meter Walk/Run Test and 5-times to Stand Test. Dyne reported efficacy data from 8 male ...

and the 10-Meter Walk/Run Test (10MWR) showed early and sustained clinical benefit at the 6.8 mg/kg Q8W dose. DYNE-101 at the 6.8 mg/kg Q8W doses showed encouraging trends on the MDHI patient ...

The last time I wrote about Dyne Therapeutics (NASDAQ:DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article ...

and 5 Times Sit to Stand Test (5xSTS), and the Myotonic Dystrophy Health Index (MDHI) patient reported outcome measure, all at 6 months compared to placebo. This cohort is expected to enroll 60 ...